News Releases

January, 2021

January 19, 2021 2021-01-19 Ready-to use self-injectable formulation of ENTYVIO® (vedolizumab) now available for Canadians for the maintenance treatment of moderately to severely active Crohn’s disease and ulcerative colitis

November, 2020

November 5, 2020 2020-11-05 Eligible patients living with rare debilitating genetic disorder are one step closer to having access to first-of-its-kind treatment option

July, 2020

July 7, 2020 2020-07-07 Takeda Canada Announces New OnePath® Patient Support Program

July 2, 2020 2020-07-02 Amalgamation of Takeda Canada Inc. and Shire Pharma Canada ULC Solidifies Company’s Leadership Position in Canadian Biopharmaceutical Industry

May, 2020

May 11, 2020 2020-05-11 Updated COVID-19 Healthcare Professional Letter

April, 2020

April 9, 2020 2020-04-09 Self-injectable formulation of ENTYVIO® (vedolizumab) approved in Canada for the maintenance treatment of moderately to severely active ulcerative colitis

March, 2020

March 16, 2020 2020-03-16 COVID19 HCP Letter

February, 2020

February 4, 2020 2020-02-04 Takeda Canada Announces Significant Investment in First Collaborative Canadian Lung Cancer Research Project with Princess Margaret Cancer Centre